Insider transactions

Jeffrey W. Albers

CIK 1638474 · CEO AND PRESIDENT · last filed 2026-08-10

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$2.28M
Companies
5
Total Filings
115
Lifetime Open-Market Net
-$66.89M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

BPMC price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
C/O ATLAS VENTURE
300 TECHNOLOGY SQ, 8TH FLOOR
CAMBRIDGE, MA 02139
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SYRE Director 24,360 $93.65 $2.28M -$2.66M 7 2026-08-10
KYMR Director 0 $111.78 $0 -$1.80M 13 2026-06-25
Blueprint Medicines Corp (BPMC) Delisted Director 0 $129.46 $0 -$62.43M 69 2025-07-21
Spyre Therapeutics, Inc. (AGLE) Delisted Director — $12.01 — $0 1 2023-11-27
Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted Director 260 $11.19 $2.9K $0 5 2022-06-30

Recent Filings · Page 8 of 12

115 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2021-11-17 Blueprint Medicines Corp (BPMC) Delisted Mixed — -$3.08M EDGAR
2021-11-03 Blueprint Medicines Corp (BPMC) Delisted Mixed — -$500.8K EDGAR
2021-08-30 Blueprint Medicines Corp (BPMC) Delisted Exer (M) +16,000 $29.9K EDGAR
2021-08-23 Blueprint Medicines Corp (BPMC) Delisted Mixed — -$2.04M EDGAR
2021-06-17 KYMR Grant (A) — $0 EDGAR
2021-06-03 Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted Grant (A) — $0 EDGAR
2021-05-14 Blueprint Medicines Corp (BPMC) Delisted Mixed — -$2.04M EDGAR
2021-03-05 Blueprint Medicines Corp (BPMC) Delisted Mixed −8,986 -$1.61M EDGAR
2021-03-03 Blueprint Medicines Corp (BPMC) Delisted Grant (A) +40,000 $0 EDGAR
2020-12-16 Blueprint Medicines Corp (BPMC) Delisted Mixed — -$551.9K EDGAR
Showing 71–80 of 115
Page 8 of 12
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.